Trial · NCT06682156
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
NCT06682156, Recruiting, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients. Trials, record NCT06682156. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06682156
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- NCT number
- NCT06682156
- Status
- Recruiting
- Enrollment
- 50 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Carfilzomib
- First posted
- 2024-11-12
- Last updated
- 2024-11-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Outcome of peripheral neuropathy | from enrollment to 2 years | recurrence of peripheral neuropathy |
| Secondary | ORR | from enrollment to 2 years | the rate of sCR,CR, PR and VGPR according to IMWG（International Myeloma Working Group） criteria |
| Secondary | sCR/CR rate | from enrollment to 2 years | the rate of sCR/CR according to IMWG criteria |
| Secondary | PR rate | from enrollment to 2 years | the rate of PR according to IMWG criteria |
| Secondary | VGPR rate | from enrollment to 2 years | the rate of VGPR according to IMWG criteria |
| Secondary | MRD negativity rate | from enrollment to 2 years | the rate of minimal residual disease |
| Secondary | AE rate | from enrollment to 2 years | the rate of adverse events |
| Secondary | 2-year OS rate | from enrollment to 2 years | the rate of Overall survival at 2 years |
| Secondary | Duration of MRD negativity | from enrollment to 2 years | Duration of minimal residual disease negativity |
| Secondary | 2-year PFS rate | from enrollment to 2 years | the rate of progression free survival at 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06682156
GET https://conductscience.org/api/trials/v1/NCT06682156/registered